Mitsu Chem Plast Q1 FY27: A sharp margin reset, capacity add-ons, and the FY28 ambition

Mitsu Chem Plast Limited began FY27 with a quarter that stood out less for headline growth and more for profitability. In Q1 FY27, consolidated total income rose to INR 95.33 crore from INR 85.40 crore in Q1 FY26. The more meaningful change came in operating performance. EBITDA increased to INR 15.49 crore, taking EBITDA margin to 16.29% versus 5.87% a year ago. Net profit increased to INR 8.74 crore from INR 1.31 crore, with net margin improving to 9.18%.

The company attributed the improvement primarily to better operating efficiency and a stronger product mix. In the earnings call, management also said it has been actively rationalising its product set, moving away from products that do not deliver adequate margins. That narrative lines up with the sharp improvement visible since FY26 Q3, culminating in the Q1 FY27 print.

At a business level, Mitsu remains a plastics processor with breadth across blow molding, injection molding and custom molding. The investor presentation positions the company across three revenue buckets: containers, furniture parts and others. It also frames a multi-year aspiration to reach INR 1,000 crore annual revenue by FY28, anchored on packaging scale-up, healthcare furniture parts under the Furnastra brand, and a pipeline of product initiatives.

Q1 FY27 performance: profitability led, not volume led

Q1 FY27 revenue growth was steady, but the quarter’s real signal was the operating leverage achieved through efficiency and mix. Consolidated revenues were INR 95.15 crore. EBITDA was INR 15.49 crore, and profit before tax was INR 11.93 crore.

Management highlighted that raw material price movements remain a feature of the business, particularly in periods of geopolitical volatility and crude-linked swings. However, in response to investor questions, management said price increases are typically passed through to customers. The timing of pass-through, as described on the call, is generally about a month in normal cases, with customer-specific discussions for specialised products.

The company also tried to set expectations on margin sustainability. While Q1 delivered a 16.3% EBITDA margin, management repeatedly stated that a sustainable margin profile is typically 10% to 12% on average, sometimes up to 10% to 13%, and that quarterly margins can vary depending on product mix.

Segment mix and what it implies

The investor presentation provides a product category revenue breakup for FY26. Containers remain the core driver, with furniture and other products providing diversification.

In FY26, category revenue (as presented) was:

During the call, management also gave a snapshot of current positioning: it stated that approximately 19.80% of today’s business includes furniture parts and other parts, and around 80% is packaging. The percentage is not perfectly aligned with the FY26 table, but both indicate the same direction. Packaging dominates, healthcare is meaningful but still secondary, and “others” is small.

This mix matters because the management commentary suggests margins are being influenced by product mix and value-added offerings. It also suggests the route to FY28 will likely remain packaging-led, with healthcare furniture and new product lines acting as accelerators rather than replacing the core.

Capacity, capex, and the mechanics of growth

Mitsu reported installed capacity of 32,450+ MT per annum in the presentation and reiterated it in the concall. It also stated capacity utilisation of 64% in FY26. Yet, the company announced an additional 3,550 MT per annum capacity addition.

In the earnings call, management clarified that this additional capacity is already operational and that it was announced after a successful run. Capex for the 3,550 MT expansion was stated as approximately INR 2 crore, funded through a mix of internal accruals and debt.

When asked why expand when utilisation is only 64%, management cited seasonality and the practical reality that some quarters can run significantly higher, even up to about 85% utilisation. It also indicated that different machines serve different product requirements, so “available capacity” is not always fungible across all orders.

Another growth lever discussed was the IBC project. Management said the IBC line would need completely different machinery and indicated that commercial production is expected approximately in Q3 FY27. It did not disclose capex numbers in the call and said details would be announced later.

Balance sheet and cash flow signals

The longer trend data in the presentation shows a balance sheet that has strengthened through FY26. Debt-to-equity declined to 0.52x in FY26, and interest coverage improved to 4.31x. Return ratios also recovered in FY26 versus FY25.

At the same time, working capital needs have increased. The working capital cycle shows net operating cycle expanding to 75 days in FY26 from 57 days in FY25, driven largely by higher debtor days (64 in FY26 versus 58 in FY25). Operating cash flow improved to INR 32.77 crore in FY26, which is a positive sign, but the working capital trend remains a key variable to monitor, especially as capacity comes online and new product programs ramp.

The stock data section of the presentation shows promoter holding at 32.23% as of June 30, 2026 and a market capitalisation of INR 222.83 crore as of August 13, 2026.

What management said to watch in FY27

On forward-looking commentary, management did not offer a numeric revenue growth target. It said it is looking for similar quarter-on-quarter growth in FY27 but emphasised that the company is focusing more on bottom-line improvement than top-line expansion.

It also acknowledged margin variability by product mix and reiterated that 10% to 12% EBITDA margin is the reasonable sustainable band, with some quarters potentially higher due to mix and efficiency.

Exports are another area where the headline narrative is larger than current scale. The presentation mentions export presence in 17 countries, but management stated exports are only around 2% of revenue currently, and that building international healthcare relationships takes time.

Takeaways

Mitsu’s Q1 FY27 outcome was a strong signal that operational initiatives and product-mix changes are translating into financial results. The company combined moderate topline growth with a step-change in margins and profit.

The near-term watchlist is clear. First, whether margins normalise back toward the 10% to 12% band management described or whether a higher band can be sustained as efficiency measures mature. Second, whether working capital intensity improves, given the rise in the net operating cycle in FY26. Third, whether the IBC project can move from a stated opportunity to a visible revenue contributor from Q3 FY27 onward.

The FY28 target of INR 1,000 crore revenue remains an ambition rather than a quantified roadmap. But the building blocks are visible in the documents: capacity additions, product launches in packaging, a formal healthcare brand in Furnastra, and a clear internal focus on pruning low-margin work. Execution across these levers will determine whether the Q1 FY27 profitability step-up becomes a new base or stays a one-quarter peak.